Abstract
Psychosomatic disorders (PSD), alternatively referred to as psychophysiologic disorders, are characterized by hypothalamic-pituitary-adrenal (HPA) axis activation, posing a substantial challenge in clinical practice. These disorders constitute a collection of intricate medical conditions marked by the considerable impact of psychological and emotional factors on the onset, intensification, or persistence of physical symptoms. The endocannabinoid system, a complex regulatory network consisting of endocannabinoids, cannabinoid receptors, and associated enzymes, emerges as a key player in modulating the body’s stress response, emotional regulation, and immune function. This review delves into the bidirectional relationship between the endocannabinoid system and the HPA axis, elucidating the impact of endocannabinoid system modulation on stress responsiveness, immune modulation, and the intricate interplay between emotional well-being and physical symptoms. Through the synthesis of current scientific knowledge, this review aims to provide a comprehensive understanding of the role of the endocannabinoid system in PSD, offering insights that may pave the way for novel therapeutic approaches.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
